Figure 4.FOXP1 was the downstream molecule of miR-122-5p. (A) The schematic diagram of binding sites between FOXP1 and miR-122-5p, and the binding capacity was evaluated by luciferase reporter assay. (B and C) Relative expression of miR-122-5p in HeLa cells with miR-122-5p mimics transfection or miR-122-5p inhibitor transfection. (D and E) Relative expression of FOXP1 in HeLa cells with miR-122-5p mimics transfection or miR-122-5p inhibitor transfection. (F and G) Relative mRNA level of FOXP1 in non-tumor tissues adjacent to cervical cancer, cervical cancer tissues and cisplatin-resistant cervical cancer tissues. (H) The protein level of FOXP1 in non-tumor tissues adjacent to cervical cancer and cervical cancer tissues. (I) The correlation between FOXP1 and miR-122-5p or lncRNA SNHG7. (J and K) Relative mRNA level of FOXP1 in human cervical epithelial cell line H8 cells, human cervical cancer cell line HeLa cells and cisplatin-resistant HeLa cells. WT FOXP1, wild type FOXP1; Mut FOXP1, mutant type FOXP1; mimics NC, negative control mimics; inhibitor NC, negative control inhibitor; N, non-tumor tissues adjacent to cervical cancer; T, cervical cancer tissues; R, cisplatin-resistant cervical cancer tissues. CR-HeLa, cisplatin-resistant HeLa cells. ***p < 0.001.
